These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7740656)

  • 1. Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
    Popert RJ; Masters JR; Coptcoat M; Zupi G
    Urol Res; 1995; 22(6):367-72. PubMed ID: 7740656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
    Harris NM; Anderson WR; Lwaleed BA; Cooper AJ; Birch BR; Solomon LZ
    Cancer; 2003 Jan; 97(1):71-8. PubMed ID: 12491507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy.
    Knuchel R; Hofstadter F; Jenkins WE; Masters JR
    Cancer Res; 1989 Mar; 49(6):1397-401. PubMed ID: 2493980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-drug resistance of a doxorubicin-resistant bladder cancer cell line.
    Floyd JW; Lin CW; Prout GR
    J Urol; 1990 Jul; 144(1):169-71. PubMed ID: 1694250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
    Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
    Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
    Harris NM; Duffy PM; Crook TJ; Anderson WR; Sharpe P; Hayes MC; Cooper AJ; Solomon LZ
    BJU Int; 2002 Dec; 90(9):957-64. PubMed ID: 12460364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
    Mizutani Y; Yoshida O; Miki T; Bonavida B
    Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent.
    Long JP; Prout GR; Wong YK; Lin CW
    J Urol; 1990 May; 143(5):1053-6. PubMed ID: 2329596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity.
    Groos E; Masters JR
    J Urol; 1986 Aug; 136(2):399-402. PubMed ID: 3090275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparative clinical trial of UFT treatment and intravesical adriamycin instillation to prevent recurrence of superficial bladder cancer].
    Masuda F; Mori Y; Torii S; Kawashima Y; Kobari T; Hosobe T
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):505-8. PubMed ID: 1558400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
    Featherstone JM; Speers AG; Lwaleed BA; Hayes MC; Cooper AJ; Birch BR
    BJU Int; 2005 May; 95(7):1091-8. PubMed ID: 15839939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-line chemotherapy with mitomycin C and lonidamine in advanced bladder cancer. Partial response in a patient with skin and lung metastases.
    Berruti A; Gerbino A; Faggiuolo R; Rovero E; Dogliotti L
    Tumori; 1995; 81(1):39-41. PubMed ID: 7754539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of electropermeabilization after the administration of anticancer drugs on transitional cell carcinoma.
    Yanai H; Kubota Y; Nakada T
    BJU Int; 2002 Mar; 89(4):438-42. PubMed ID: 11872039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
    Miller RS; Torti FM
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept.
    Laihia JK; Pylkkänen L; Laato M; Boström PJ; Leino L
    BJU Int; 2009 Nov; 104(9):1233-8. PubMed ID: 19466948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
    Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
    Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M; McGarry R; Kupelnick B
    Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The activity of etoposide (VP16) in combination chemotherapy against human bladder cancer cells in vitro].
    Hattori T; Satoh M; Terashima Y; Nishimura T; Akimoto M
    Hinyokika Kiyo; 1991 Sep; 37(9):995-8. PubMed ID: 1785427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.